Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ACE | P12821 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | INMT | O95050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclocreatine SCHEMBL7935371 | 1.00 | CYP2D6 (0.39) | CYP2D6CYP2C19POLBCYP2C9KMT2A | |
| Cyclocreatine SCHEMBL11796002 | 0.98 | CYP2D6 (0.38) | CYP2D6CYP2C19POLBCYP2C9KMT2A | |
| Cyclocreatine SCHEMBL1980714 | 0.96 | CYP2D6 (0.37) | CYP2D6CYP2C19POLBCYP2C9KMT2A | |
| Cyclocreatine SCHEMBL1981687 | 0.91 | INMT (0.40) | CYP2D6CYP2C19POLBCYP2C9KMT2A | |
| SCHEMBL448277 | 0.89 | ACE (0.39) | CYP2D6CYP2C19POLBCYP2C9KMT2A | |
| Cyclocreatine SCHEMBL936945 | 0.88 | TSHR (0.33) | CYP2D6CYP2C19POLBCYP2C9KMT2A | |
| Cyclocreatine SCHEMBL1980609 | 0.83 | SMN1; SMN2 (0.44) | CYP2D6CYP2C19POLBCYP2C9KMT2A | |
| SCHEMBL19719147 | 0.82 | — | — | |
| SCHEMBL14537232 | 0.82 | BDKRB2 (0.33) | KMT2ATSHRINMT | |
| Cyclocreatine SCHEMBL9074350 | 0.82 | CRBN (0.35) | CYP2D6CYP2C19POLBCYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1400 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12226382-B2 | Methods for treating microglial dysfunction | WASHINGTON UNIVERSITY (US) | 2025-02-18 | — | — | US | claimed |
| CN-119386010-A | Application of cyclocreatine in preparation of medicine for treating diffuse large B cell lymphoma | 南通市第一人民医院 | 2025-02-07 | — | — | CN | claimed |
| US-20240327437-A1 | DE NOVO Synthesis of Cyclocreatine and Subsequent Conversion to Cyclocreatine Phosphate Via a Continuous Flow Reactor (CFR) System | NOUR HEART, INC. | 2024-10-03 | — | — | US | claimed |
| US-20240218051-A1 | MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION | GENZYME CORPORATION | 2024-07-04 | — | — | US | claimed |
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | claimed |
| EP-4373582-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | Inspirna, Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| CN-111328330-B | Phosphoplatin compounds as immunomodulators and their therapeutic use | 普罗蒙托里治疗有限公司 | 2024-03-08 | — | — | CN | claimed |
| US-11879004-B2 | Modified binding polypeptides for optimized drug conjugation | GENZYME CORPORATION (US) | 2024-01-23 | — | — | US | claimed |
| US-20230391849-A1 | MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION | GENZYME CORPORATION | 2023-12-07 | — | — | US | claimed |
| CN-117089615-A | Application of creatine metabolism inhibitor in killing glioma stem cells | 中国科学技术大学 | 2023-11-21 | — | — | CN | claimed |
| WO-1995019769-A1 | COMBINATIONS OF A CREATINE COMPOUND WITH A HYPERPLASTIC INHIBITORY AGENT FOR INHIBITING UNDESIRABLE CELL GROWTH | AMIRA, INC. (US) | 1995-07-27 | — | — | WO | claimed |
| EP-0660709-A1 | CREATINE ANALOGS HAVING ANTIVIRAL ACTIVITY | AMIRA, INC. (US) | 1995-07-05 | — | — | EP | claimed |
| WO-1994026261-A1 | TREATING BODY PARTS SUSCEPTIBLE TO ISCHEMIA USING CREATINE ANALOGS | AMIRA, INC. (US) | 1994-11-24 | — | — | WO | claimed |
| WO-1994016687-A1 | USE OF CREATINE OR ANALOGS FOR THE MANUFACTURE OF A MEDICAMENT FOR INHIBITING TUMOR GROWTH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1994-08-04 | — | — | WO | claimed |
| US-5324731-A | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated | AMIRA, INC. (US) | 1994-06-28 | — | — | US | claimed |
| US-5321030-A | Administering for treatment or prevention | AMIRA, INC. (US) | 1994-06-14 | — | — | US | claimed |
| EP-0557383-A1 | METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED | AMIRA, INC. (US) | 1993-09-01 | — | — | EP | claimed |
| WO-1993012781-A2 | CREATINE ANALOGS HAVING ANTIVIRAL ACTIVITY | AMIRA, INC. (US) | 1993-07-08 | — | — | WO | claimed |
| WO-1992008456-A2 | METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED | AMIRA, INC. (US) | 1992-05-29 | — | — | WO | claimed |
| US-5091404-A | Administering cyclocreatire, antiischemic agents | UNIVERSITY OF CONNECTICUT, THE | 1992-02-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11879004-B2 | Modified binding polypeptides for optimized drug conjugation | FCGR3B, CD2BP2, FCGR2A | CYP2D6 1785/4885CYP2C19 3118/4885POLB 4109/4885 |
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | CYP2D6 2098/4885CYP2C19 2097/4885POLB 262/4885 |
| US-20240218051-A1 | MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION | FCGR3B, CD2BP2, FCGR2A | CYP2D6 1785/4885CYP2C19 3118/4885POLB 4109/4885 |
| US-20230391849-A1 | MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION | FCGR3B, CD2BP2, FCGR2A | CYP2D6 1785/4885CYP2C19 3118/4885POLB 4109/4885 |
| US-20240327437-A1 | DE NOVO Synthesis of Cyclocreatine and Subsequent Conversion to Cyclocreatine Phosphate Via a Continuous Flow Reactor (CFR) System | PCK1, PNKP, PFKFB4 | CYP2D6 983/4885CYP2C19 1264/4885POLB 38/4885 |
| US-12226382-B2 | Methods for treating microglial dysfunction | CHRNB2, PSEN2, CX3CR1 | CYP2D6 4735/4885CYP2C19 4703/4885POLB 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.